[CAS NO. 408504-26-7] Sergliflozin etabonate

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [408504-26-7]

Catalog

HY-12611

Brand

MCE

CAS

408504-26-7

DESCRIPTION [408504-26-7]

Overview

MDL	-
Molecular Weight	448.46
Molecular Formula	C23H28O9
SMILES	COC(C=C1)=CC=C1CC(C=CC=C2)=C2O[C@@H]3O[C@@H]([C@H]([C@@H]([C@H]3O)O)O)COC(OCC)=O

For research use only. We do not sell to patients.

Summary

Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes ^[1] .

IC50 & Target

SGLT2

In Vivo

Sergliflozin etabonate (1, 3, 10, 30 mg/kg; oral; once) significantly reduces non-fasting blood glucose levels in KK-Ay mice in a dose-dependent manner ^[1] .
Sergliflozin etabonate (1.7, 8.4, 45.7 mg/kg in the 0.001, 0.005, and 0.025% sergliflozin etabonate; fed; daily for 9 weeks) reduces non-fasting blood glucose level and decreases triglyceride content in the liver in a dose-dependent manner in KK-Ay mice ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	14 weeks, Female KK-Ay mice ^[1]
Dosage:	1, 3, 10, 30 mg/kg
Administration:	Oral; once
Result:	Significantly reduced non-fasting blood glucose level with the reduction in blood glucose level at 2 h post dosing in the 1 mg/kg group, 3 mg/kg group, 10 mg/kg group, and 30 mg/kg group was 12, 15, 28, and 39%, respectively.

Animal Model:	4 weeks, Female KK-Ay mice ^[1]
Dosage:	1.7, 8.4, 45.7 mg/kg in the 0.001, 0.005, and 0.025% sergliflozin etabonate
Administration:	Fed, daily for 9 weeks
Result:	Reduced non-fasting blood glucose level and decreased triglyceride content in the liver in a dose-dependent manner in diabetic control KK-Ay mice.

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Katsuno K, et al. Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice. Eur J Pharmacol. 2009 Sep 15;618(1-3):98-104.